Category Archives: Strategy
By Ben Comer | Published: November 25, 2013
FDA’s new Breakthrough Therapies designation sped Pharmacyclics/J&J’s ibrutinib (brand name: Imbruvica) through regulatory review in four months, based on Phase 2 studies. Pricing and access issues, though, may not get resolved so quickly.
By Guest Blogger | Published: November 22, 2013
How Pro-active is Your Anti-Bribery Strategy? Most multinationals are already familiar with the Foreign Corrupt Practices Act (FCPA). US regulators have been aggressively prosecuting companies and individuals for bribery with increasing zeal for the past decade, with healthcare companies being specially targeted. Recently, leading manufacturers of orthopedic implants: Zimmer, Depuy, Smith & Nephew, Biomet and Stryker [...]
By Marylyn Donahue | Published: November 20, 2013
The radical shift currently taking place in pharma marketing is all about partnering with patients rather than talking at them. In other words, pharma and patients are becoming friends who can help their “partners” educate, design a diet plan, increase disease awareness, and take you to the doctor…well, not quite yet.
By Guest Blogger | Published: November 19, 2013
by Maria Pinelli EY Global Vice Chair, Strategic Growth Markets “Leaning in” might be all the rage – but “hanging in” is just as important to make sure women gather momentum in the workplace. At a meeting of the Global Women in Business Advisory Council last week in Palm Springs, CA, members discussed ways to build [...]
By Ben Comer | Published: November 14, 2013
Can big pharma solve its fixed cost problem by going virtual? Not entirely, but drug companies can get more out of their CRO partners by treating them less like avatars and more like equals, according to conference-goers at a CBI event in The Triangle. The problem with overbearing project mangers on the sponsor side of the [...]